Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Company news
Company news
Team ChemDiv, Inc. at AACR 2024, San Diego!
Last week, our team had the incredible opportunity to attend the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
AACR 2024
Excited for AACR 2024, we invite you to meet our executive team, led by CEO Bill Farley.
The Drug Discovery Chemistry conference in San Diego.
Last week, our ChemDiv team, Michael Nyman, Roman Timakhov, and Aleksandra Khotimchenko, had the incredible opportunity to attend the Drug Discovery Chemistry conference in sunny San Diego.
Meet ChemDiv at Drug Discovery Chemistry in San Diego, April 1-4.
We're thrilled to announce that our team members, Roman Timakhov and Aleksandra Khotimchenko, will be attending the Drug Discovery Chemistry in San Diego, April 1-4.
Meet ChemDiv at the 42nd Annual JPM Healthcare Conference in San Francisco
42nd Annual JPM Healthcare Conference, held from January 8th to 11th, 2024, in San Francisco, CA.
ChemDiv Marks a Milestone
ChemDiv Marks a Milestone as Orionis Biosciences' Novel Immunotherapy Enters Phase I Clinical Trials
ChemDiv Forges Strategic Partnership with The University of Texas Medical Branch (UTMB)
To Expand Its High-throughput Screening Research Capabilities.
ChemDiv Helps Advance Viriom's Influenza Treatment to Successful Phase
ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms, announces successful completion of Phase I clinical trials for AV51...
Bill Farley Named New CEO of ChemDiv
Veteran Pharma and Biotech Executive Bill Farley Named New CEO of ChemDiv
Happy Holidays from ChemDiv Inc
Happy Holidays from ChemDiv Inc
Presented Non-Clinical Summary Data for The Best-in-Class Selective BCL2
Investigators from John Byrd's Lab at University of Cincinnati Presented Non-Clinical Summary Data for The Best-in-Class Selective BCL2 Inhibitor Clinical Candidate Developed by Eilean Therapeutics in...
ChemDiv Presented Non-Clinical Summary Data
ChemDiv Presented Non-Clinical Summary Data for The Best-in-Class Selective FLT3 Clinical Candidate at the 65th ASH Annual Meeting and Exposition with Its Partners and Sponsors ...
1
2
3
4
5